Remternetug

Summary

Remternetug (CHEMBL5095484) is a phase-3 clinical-stage antibody; indicated across 1 condition including alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 1 condition
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095484
Name	Remternetug
Type	Antibody
Max phase	3

Also known as: LY-3372993, LY3372993, Remternetug, REMTERNETUG

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	3	MONDO:0004975	MONDO:0004975

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE1	4
PHASE3	2
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05552157	PHASE2/PHASE3	RECRUITING	A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06647498	PHASE2/PHASE3	RECRUITING	A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06653153	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Remternetug (LY3372993) in Early Alzheimer’s Disease (TRAILRUNNER-ALZ 3)
NCT05463731	PHASE3	COMPLETED	A Study of Remternetug (LY3372993) in Participants With Alzheimer’s Disease (TRAILRUNNER-ALZ 1)
NCT07346495	PHASE1	ACTIVE_NOT_RECRUITING	A Study of Remternetug (LY3372993) in Healthy Chinese Participants
NCT03720548	PHASE1	COMPLETED	A Study of LY3372993 in Healthy Participants and Participants With Alzheimer’s Disease (AD)
NCT04451408	PHASE1	COMPLETED	A Study of LY3372993 in Participants With Alzheimer’s Disease (AD) and Healthy Participants
NCT07056309	PHASE1	COMPLETED	A Study of Remternetug (LY3372993) in Healthy Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).